Stcube announces interim results from Phase 2 trial in non-small cell lung cancer… 73% patient enrollment
Predicted impact: Medium
Phase 2 interim results for lung cancer drug; material for a ₩471B company.
Stcube에스티큐브
052020 · KOSDAQ · ₩052020 · 에스티큐브
₩6,580▼ ₩360 (5.19%)End-of-day · Oct 30, 2026 · End-of-day prices.
STcube unveils three development axes for nelmastobart at ESMO, announces combination expansion strategy
Predicted impact: Low· Actual: +9.2% vs sector, volume 0.8× normal (5 trading days)
ESMO data presentation was already announced in the last 14 days.
S-Cube Presents Three Studies on Nemvastobart at ESMO, Outlines Combination Therapy Expansion Strategy
Predicted impact: Low· Actual: +9.2% vs sector, volume 0.8× normal (5 trading days)
Conference presentations of drug study data; no revenue size disclosed, routine clinical news.
Also known as: Stcube / 에스티큐브 / 052020 / KRX:052020
Source: KRX statistical information